Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levofloxacin vs Cefuroxime Axetil for Acute Bacterial Exacerbation of Chronic Bronchitis
NCT00269932Phase 3Completed
- Sponsor
- Johnson & Johnson
- Start
- Aug 1993
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of levofloxacin in chronic bronchitis (CB) (2 arms), sponsored by Johnson & Johnson. Primary endpoint: Clinical response rate (reduction in signs and symptoms). Started Aug 1993; status: completed.
02
Drugs
levofloxacin
03
Conditions
chronic bronchitis (CB)
Beyond the preview
Go deeper on NCT00269932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00269932.